Funding for this research was provided by:
Foundation for the National Institutes of Health (CA180888, CA180819, CA180826, CA180801, CA180858)
Breast Cancer Research Foundation (NA, NA, NA)
Susan G. Komen (NA)
Received: 12 October 2018
Accepted: 12 March 2019
First Online: 10 April 2019
Ethics approval and consent to participate
: The study was approved by the NCI and the Yale Cancer Center Human Investigations Committee.
: Not applicable
: SW, AC, ML, PD and NE are employees of Nanostring Technologies. VP is now an employee of Sanofi Aventis. LP has received consulting fees and honoraria from, Astra Zeneca, Merck, Novartis, Genentech, Eisai, Pieris, Immunomedics, Seattle Genetics, Almac and Syndax.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.